Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non Operating Income (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Non Operating Income for 5 consecutive years, with -$831000.0 as the latest value for Q1 2026.

  • For Q1 2026, Non Operating Income rose 94.62% year-over-year to -$831000.0; the TTM value through Mar 2026 reached -$77.8 million, down 157.69%, while the annual FY2025 figure was -$61.3 million, 765662.5% down from the prior year.
  • Non Operating Income hit -$831000.0 in Q1 2026 for Phathom Pharmaceuticals, up from -$61.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $24.4 million in Q4 2023 and bottomed at -$61.1 million in Q4 2025.
  • Average Non Operating Income over 5 years is -$7.1 million, with a median of -$831000.0 recorded in 2026.
  • Year-over-year, Non Operating Income soared 27207.78% in 2023 and then plummeted 264666.67% in 2025.
  • Phathom Pharmaceuticals' Non Operating Income stood at -$90000.0 in 2022, then skyrocketed by 27207.78% to $24.4 million in 2023, then plummeted by 99.8% to $49000.0 in 2024, then tumbled by 124744.9% to -$61.1 million in 2025, then surged by 98.64% to -$831000.0 in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$831000.0, -$61.1 million, and -$7000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.